U.S. Expected to Remain Growth Engine of Atrial Fibrillation Market during the Forecast Period 2013 – 2019
The atrial fibrillation market on the basis of geography is segmented into four regions namely North America, Asia-Pacific, Europe and rest of the world (RoW). The North American atrial fibrillation market held majority of the market share in 2012 on account of the following factors:
High prevalence of atrial fibrillation. According to the estimates of the U.S. CDC, the prevalence of atrial fibrillation was 2.66 million in 2010. Moreover, its prevalence is estimated to reach 12 million by 2050.
The high atrial fibrillation prevalence coupled with the presence of high disposable incomes of patients, the presence of a robust reimbursement infrastructure and rising healthcare expenditure are some of the major factors driving the growth of North America atrial fibrillation market.
The North American region was followed by Europe in terms of market share in 2012. The Asia-Pacific atrial fibrillation market is expected to grow at the highest CAGR on account of the rising prevalence of atrial fibrillation in China coupled with the introduction of new healthcare reforms and rapid economic development in the country.
Request Sample Copy of the Report @ https://goo.gl/32sfPT
In terms of treatment types, the overall atrial fibrillation market is segmented into two type’s namely pharmacological and non-pharmacological treatment markets. The global atrial fibrillation treatment market was dominated by the pharmacological treatment procedures (involving anti-arrhythmic drugs, rate control drugs, chemical cardioversion and anti-coagulants) in terms of market share in 2012. This valuation is justified by the following reasons:
Drugs are consumed more frequently by patients, sometimes simultaneously with non-pharmacological treatment procedures. For e.g. patients are advised to consume anti-coagulant drugs before an electric cardioversion and patients are administered with anti-coagulants post a catheter ablation procedure to reduce the risk of a stroke.
Drugs are a cheaper alternative to expensive non-pharmacological procedures such as catheter ablation and surgeries. However, this fact is not applicable to all the patients as in most of the cases cardiologists recommend the most appropriate and therefore inevitable treatment procedures to patients suffering from atrial fibrillation.
Read Complete Report @ http://www.mrrse.com/atrial-fibrillation-market
The market share of pharmacological treatment procedures is expected to increase to over 55% in 2019 on account of the introduction of new and advanced drugs such as anti-coagulants dabigatran and rivaroxaban.
Table of Content
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Market Overview
Chapter 4 Atrial Fibrillation Market, by Treatment Types
Chapter 5 Atrial Fibrillation Market, by Geography
Chapter 6 Competitive Landscape
Chapter 7 Recommendations
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.
90 State Street, Suite 700
Albany, NY 12207